Evidence map›Paper›PMID 35508819›Full record

ArticleNeurosurgical review2022

Probing individual-level structural atrophy in frontal glioma patients.

Guobin Zhang, Xiaokang Zhang, Huawei Huang, Yonggang Wang, Haoyi Li, Yunyun Duan, Hongyan Chen, Yaou Liu, Bin Jing, Yanmei Tie and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. [Research Progress in Imaging Investigation of TERT Promoter Mutations in Gliomas].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Guobin ZhangDepartment of Neurosurgery, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Xiaokang ZhangDepartment of Neurosurgery, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Huawei HuangDepartment of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Yonggang WangDepartment of Neurosurgery, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Haoyi LiDepartment of Neurosurgery, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Yunyun DuanDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Hongyan ChenDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Yaou LiuDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Bin JingSchool of Biomedical Engineering, Capital Medical University, Beijing, 100069, China. bjing@ccmu.edu.cn.
Yanmei TieDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. ytie@bwh.harvard.edu.
Song LinDepartment of Neurosurgery, China National Clinical Research Center for Neurological Diseases (NCRC-ND), Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China. linsong_ttyy@sina.com.ORCID http://orcid.org/0000-0002-1760-1887
Capital Medical University · CNBrigham and Women's Hospital · US

Funding

Beijing Hospital Authority Youth Program 20190504Beijing Municipal Commission of Education KM202010025025Beijing Outstanding Talent Training Foundation 2018000021469G230National Natural Science Foundation of China 81801042
6 · The paper itself

Abstract

Although every glioma patient varies in tumor size, location, histological grade and molecular biomarkers, non-tumoral morphological abnormalities are commonly detected by a statistical comparison among patient groups, missing the information of individual morphological alterations. In this study, we introduced an individual-level structural abnormality detection method for glioma patients and proposed several abnormality indexes to depict individual atrophy patterns. Forty-five patients with a glioma in the frontal lobe and fifty-one age-matched healthy controls participated in the study. Individual structural abnormality maps (SAM) were generated using patients' preoperative T1 images, by calculating the degree of deviation of voxel volume in each patient with the normative model built from healthy controls. Based on SAM, a series of individual abnormality indexes were computed, and their relationship with glioma characteristics was explored. The results demonstrated that glioma patients showed unique non-tumoral atrophy patterns with overlapping atrophy regions mainly located at hippocampus, parahippocampus, amygdala, insula, middle temporal gyrus and inferior temporal gyrus, which are closely related to the human cognitive functions. The abnormality indexes were associated with several molecular biomarkers including isocitrate dehydrogenase (IDH) mutation, 1p/19q co-deletion and telomerase reverse transcriptase (TERT) promoter mutation. Our study provides an effective way to access the individual-level non-tumoral structural abnormalities in glioma patients, which has the potential to significantly improve individualized precision medicine.

Indexed as

Brain NeoplasmsGliomaTelomeraseAtrophyHumansIsocitrate DehydrogenaseMutationIsocitrate DehydrogenaseTelomeraseAbnormality indexFrontal gliomaIndividual structural atrophyMolecular biomarkersStructural MRI

Identifiers

PMID35508819
OpenAlexW4229017066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.